Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long‐Term Urate‐Lowering Therapy in the American College of Rheumatology RISE Registry
Authors' conclusion
Among gout patients receiving long-term ULT followed longitudinally by rheumatologists, more than half had a documented SU, and among those tested, three-quarters achieved the recommended SU target.
Study context
- Population
- Gout patients with ≥1 gout diagnosis in 2018–2019 and continuous urate-lowering therapy (ULT) use for ≥12 months, followed by rheumatologists in the American College of Rheumatology's (ACR) RISE registry (mean age 67.2 years; 73.5% male; 32.3% non-White)
- Participants
- 9,560 patients
- Outcome
- SU monitoring (≥1 SU recorded) and, among those tested, achievement of SU <6.0 mg/dl
- Follow-up
- Measurement year
Methodological detailsregistry-based (ACR RISE registry), multilevel logistic regression
- Registry-based (ACR RISE registry)
- Multilevel logistic regression
Main finding
As reported in the abstract
Patients with at least 1 serum urate (SU) recorded
56%
Achieved SU target, among patients with at least 1 SU recorded
74%
Observational data: associations, not effects.
Further findings
Factors associated with SU testing and target SU achievement (multivariate)
- Non-White patients slightly less likely to be tested or achieve a target SU
Original publication
Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long‐Term Urate‐Lowering Therapy in the American College of Rheumatology RISE Registry. Arthritis Care Res (Hoboken). Published 3 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →